Advanced Life Sciences Announces Results of Shareholder Meeting
At the meeting, the shareholders elected Dr. Michael T. Flavin and Messrs.Scott F. Meadow and Thomas V. Thornton to the Company's Board of Directorseach for a term of three years and ratified the appointment of Deloitte &Touche LLP as the Company's independent registered public accounting firm forfiscal year 2008. The shareholders also approved the amendment of theCompany's stock incentive plan to provide 1,900,000 additional stock optionsfor future grant by the Company to attract and retain talented professionalsand achieve continued success and growth.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in thediscovery, development and commercialization of novel drugs in the therapeuticareas of infection, cancer and respiratory diseases. The company's leadcandidate, cethromycin, is a novel once-a-day antibiotic in late-stagedevelopment for the treatment of respiratory tract infections. For moreinformation, please visit us on the web athttp://www.advancedlifesciences.com.
Any statements contained in this press release that relate to futureplans, events or performance are forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Except for historicalinformation, the statements made in this press release are forward-lookingstatements about Advanced Life Sciences Holdings, Inc., including statementsregarding the clinical trials and regulatory pathway of cethromycin.Forward-looking statements represent our management's judgment regardingfuture events and are accurate at the time they are made. The Company doesnot undertake any obligations to update any forward-looking statements whetheras a result of new information, future events or otherwise. Our actualresults could differ materially from those discussed herein due to severalfactors including the success and timing of our clinical trials and ourability to obtain and maintain regulatory approval and labeling of our productcandidates; our plans to develop and commercialize our product candidates; theloss of key scientific or management personnel; the size and growth ofpotential markets for our product candidates and our ability to serve thosemarkets; regulatory developments in the U.S. and foreign countries; the rateand degree of market acceptance of any future products; the accuracy of ourestimates regarding expenses, capital requirements, and our ability to accesscapital through partnerships, stock offerings and future revenues; our abilityto obtain and maintain intellectual property protection for our productcandidates; the successful development of our sales and marketingcapabilities; the success of competing drugs that become available; and theperformance of third party collaborators and manufacturers. These andadditional risks and uncertainties are detailed in the Company's filings withthe Securities and Exchange Commission.
SOURCE Advanced Life Sciences Holdings, Inc.
You May Also Like